In patients with chronic renal failure (eGFR ≥ 30 mL/min/1.73 m²), how should tofacitinib be dosed, monitored, and what are the contraindications and alternative therapies?

Tofacitinib Dosing in Chronic Renal Failure

In patients with chronic renal failure (eGFR ≥30 mL/min/1.73 m²), reduce tofacitinib to half the standard dose—if taking 10 mg twice daily, reduce to 5 mg twice daily; if taking 5 mg twice daily, reduce to 5 mg once daily. 1

Dose Adjustments by Renal Function

Moderate to Severe Renal Impairment (CrCl 30-60 mL/min or eGFR ≥30 mL/min/1.73 m²)

• Standard dosing requires reduction by 50%: 1

  • 10 mg twice daily → 5 mg twice daily
  • 5 mg twice daily → 5 mg once daily
  • 22 mg once daily (XR) → 11 mg once daily
  • 11 mg once daily (XR) → 5 mg once daily (immediate-release)

• Pharmacokinetic rationale: AUC increases by approximately 143% in moderate renal impairment and 223% in severe renal impairment compared to normal renal function, while Cmax remains similar across groups 2

• The consensus guideline recommends dose reduction for creatinine clearance 30-60 mL/min, with severe impairment (CrCl <30 mL/min) requiring reduction to 5 mg once daily 3

End-Stage Renal Disease (ESRD) on Hemodialysis

• Use the same reduced dosing as severe renal impairment (5 mg once daily for standard dosing) 1

• Administer dose after dialysis session on dialysis days—if a dose was taken before dialysis, do not give supplemental doses 1

• Mean AUC in ESRD patients is approximately 40% higher than in healthy subjects, but dialysis efficiency is limited (mean dialyzer efficiency 0.73) due to extensive non-renal clearance (70% hepatic metabolism) 1, 2

Laboratory Monitoring Requirements

Baseline Assessment Before Initiation

• Complete blood count with differential, liver transaminases, creatinine/eGFR, and lipid panel 3

Follow-Up Monitoring Schedule

Intensive early monitoring followed by regular surveillance: 3

• At 1 month: Full blood count with differential, transaminases, renal function
• At 3 months: Full blood count with differential, transaminases, renal function, plus lipid levels
• Every 3 months thereafter: Full blood count with differential, transaminases, renal function

Specific Laboratory Thresholds Requiring Action

Hemoglobin: 3

• ≥90 g/L with ≤20 g/L decrease: Continue current dose
• <80 g/L (confirmed by repeat): Interrupt dosing until normalized
• Decrease >20 g/L: Interrupt dosing until normalized

Absolute Neutrophil Count (ANC): 3, 1

• 1000 cells/mm³: Continue current dose

• 500-1000 cells/mm³ (two sequential measures): Reduce dose or temporarily discontinue until >1000 cells/mm³
• <500 cells/mm³: Discontinue permanently

Absolute Lymphocyte Count (ALC): 3

• 750 cells/mm³: Continue current dose

• 500-750 cells/mm³ (two sequential measures): Reduce dose or temporarily discontinue until >750 cells/mm³
• <500 cells/mm³: Discontinue permanently (significantly increases opportunistic infection risk)

Liver Transaminases: 3

• Monitor periodically; avoid in severe hepatic impairment (Child-Pugh C)
• Moderate hepatic impairment (Child-Pugh B) requires dose reduction to 5 mg once daily

Contraindications and Precautions

No Absolute Contraindications

• The FDA label states "None" for formal contraindications 1

Critical Safety Warnings in CKD Population

Serious infections are the primary concern: 1, 4

• Avoid use in patients with active serious infections, including localized infections 1
• Bacterial, mycobacterial (tuberculosis), invasive fungal, viral, and opportunistic infections reported 1
• Infection rates are higher with tofacitinib versus TNF inhibitors, with hazard ratio 1.48 (95% CI 1.17-1.87) for serious infections at 10 mg twice daily 4
• Risk increases substantially in patients ≥65 years compared to 50-<65 years 4

Additional risk factors for serious infections across all treatments: 4

• Increasing age
• Baseline opioid use
• History of chronic lung disease
• Time-dependent oral corticosteroid use

Gastrointestinal perforation risk: 3

• Evaluate new abdominal symptoms promptly
• Fever and acute phase reactants may be blunted by JAK inhibitor therapy

Important Monitoring Caveat

Acute phase reactants (CRP, ESR) are reduced independently of disease activity improvement: 3

• Use disease activity scores that do not rely heavily on inflammatory markers (e.g., CDAI in rheumatoid arthritis rather than DAS28)
• This is critical for accurately assessing treatment response

Alternative Therapies

When to Consider Alternatives

Severe renal impairment (CrCl <30 mL/min): 3

• Baricitinib (another JAK inhibitor) should not be used at all in this population
• Consider alternative immunosuppression depending on underlying condition

Persistent cytopenias despite dose reduction: 3, 1

• If ANC <500 cells/mm³ or ALC <500 cells/mm³ persists, discontinue permanently
• Consider switching to biologics with different mechanisms (TNF inhibitors, IL-6 inhibitors, etc.)

Recurrent serious infections: 4

• Given the 48% higher serious infection rate versus TNF inhibitors, consider switching to alternative immunosuppression
• This is particularly important in patients ≥65 years or with chronic lung disease

Skin Cancer Surveillance

• Annual formal skin examination recommended due to increased risk of non-melanoma skin cancer, possibly related to prior methotrexate and TNF inhibitor exposure 3

Clinical Pearls

• Tofacitinib clearance is approximately 70% hepatic and 30% renal, explaining why dose reduction (not avoidance) is appropriate in moderate-severe CKD 1
• The extended half-life in renal impairment (increasing with severity) justifies once-daily dosing in severe impairment 2
• In transplant settings, long-term tofacitinib preserved renal function better than cyclosporine but was associated with persistent serious infection risk when combined with mycophenolic acid products 5